Author

M. Szpakowska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Chevigne· 4 shared C. de Graaf· 2 shared H. F. Vischer· 2 shared I. J. P. de Esch· 2 shared M. Wijtmans· 2 shared R. Leurs· 2 shared A. D. Windhorst· 1 shared A. Elvington· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

A. Chevigne

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma

M. Z. Noman, M. Szpakowska, M. Xiao, K. Van Moer, M. Ollert, G. Berchem, A. Chevigne, B. Janji

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.

bioRxiv · Apr 2, 2024 · PreprintCancer Biology

Design, synthesis and pharmacological characterization of the first photoswitchable small-molecule agonist for the Atypical Chemokine Receptor 3

S. Berenger, J. M. Adamska, F. Deflorian, C. de Graaf, C. B. Palmer, M. Szpakowska, A. Chevigne, I. J. P. de Esch, B. Zarzycka, H. F. Vischer, M. Wijtmans, R. Leurs

This paper designs and characterizes the first photoswitchable small-molecule agonist for ACKR3, showing its selectivity and light-controlled activation properties.

bioRxiv · Mar 20, 2024Pharmacology & Toxicology

Pharmacological characterization and radiolabeling ofVUF15485, a high-affinity small-molecule agonist for theatypical chemokine receptor ACKR3

A. Zarca, I. Adlere, C. P. Viciano, M. Arimont-Segura, M. Meyrath, I. A. Simon, J. P. M. Bebelman, D. Laan, H. G. J. Custers, E. C. Janssen, K. L. Versteegh, R. Bosma, I. J. P. De Esch, H. F. Vischer, M. Wijtmans, , R. Leurs

This paper characterizes VUF15485, a high-affinity ACKR3 agonist, and reports its radiolabeling and binding properties.

bioRxiv · Jul 12, 2023Pharmacology & Toxicology

CXCR4-binding PET tracers link monocyte recruitment and endothelial injury in murine atherosclerosis

G. J. Randolph, A. Elvington, O. Baba, D. Sultan, G. S. Heo, X. Zhang, H. Luehmann, L. Detering, M. Szpakowska, A. Chevigne, Y. Liu

This study shows that a CXCR4-binding PET tracer accumulates in atherosclerotic plaques due to endothelial CXCR4 expression, linking endothelial injury to monocyte recruitment.

bioRxiv · Jan 2, 2020Pathology